Healthcare Utilization and Costs Among Hospitalized Patients With Cardiomyopathy

Cardiomyopathy is the most common inherited cardiovascular disease, showing family aggregation, and it has a huge psychological and economic burden on family members. In this study, the investigators collected clinical information and costs of patients hospitalized with cardiomyopathy and establish a database to characterize real-world cost profile and inform cost management of cardiomyopathy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cardiomyopathies Cardiovascular Diseases Cost Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Fuwai hospital, Beijing, Beijing 100037

Beijing, China

About this study

This study conducted a retrospective survey of hospitalized patients with cardiomyopathy aged ≥18 years in 13 centers in China from March 1, 2017 to March1, 2022. The investigators collected clinical information, healthcare utilization and cost data of patients hospitalized with cardiomyopathy so as to characterize real-world cost profile and inform cost management of cardiomyopathy in China.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Hospitalized patients with primary discharge diagnosis meeting one of the following subtypes of cardiomyopathy were enrolled, including HCM, DCM, ACM, RCM, left ventricular non-compaction, cardiac amyloidosis, Fabry disease, Pompe disease, Danon disease, and PRKAG2 cardiac syndrome.

Exclusion criteria

Records with a "likely" or "probable" diagnosis of cardiomyopathy were excluded.

Treatment and study plan

Primary outcomes

total cost per hospital admission

Time frame: through hospitalization completion, an average of 10 days

Total cost per hospital admissionin is total expenditures made towards a given hospital admission, including the portion paid by the health plan and any out-of-pocket costs paid by enrollees under the plan's cost sharing.The composition of the total cost of hospitalization by categorizing itemized costs into the following groups: total medical consumables cost, total diagnosis-related cost, total treatment cost (e.g., cost of operation), total Western medicine cost, total services cost, total blood and blood products cost, total traditional Chinese medicine cost, total traditional Chinese treatment cost, total rehabilitation cost, and other costs.

Sponsors and collaborators

Lead sponsor

China National Center for Cardiovascular Diseases

Other Gov

Registry information

Important dates

Study start: 2017
Primary completion: 2022
Study completion: 2026
First posted: Mar 25, 2025
Registry last updated: May 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed